Transdermal delivery of botulinum toxin-A through phosphatidylcholine/cholesterol nanoliposomes for treatment of post-acne scarring.

IF 4.2 3区医学 Q2 ENGINEERING, BIOMEDICAL Journal of Materials Science: Materials in Medicine Pub Date : 2024-07-29 DOI:10.1007/s10856-024-06810-1

Lannan Chen, Lei Cui, Jiabing Ran, Zhengrui Liu, Xiongbin Zhu

{"title":"Transdermal delivery of botulinum toxin-A through phosphatidylcholine/cholesterol nanoliposomes for treatment of post-acne scarring.","authors":"Lannan Chen, Lei Cui, Jiabing Ran, Zhengrui Liu, Xiongbin Zhu","doi":"10.1007/s10856-024-06810-1","DOIUrl":null,"url":null,"abstract":"<p><p>As an acne sequela, post-acne scarring (PSA) has huge negative impact on sufferers' quality of life because of aesthetical embarrassment. Transdermal delivery of botulinum toxin-A (BTXA) is a promising strategy for PAS treatment, but currently reported approaches are far from satisfactory. In this work, phosphatidylcholine/cholesterol (PC/Chol) nanoliposomes were utilized for encapsulation and transdermal delivery of BTXA. The composition, structure, morphology, size, size distribution, etc. of as-prepared BTXA@liposome nanoparticles were investigated in detail. Simulated transdermal delivery assay indicated that the diffusion depth of the BXTA@liposome nanoparticles was nearly 8 times that of pure BTXA and reached 380 μm. 12 facial PSA patients were recruited to evaluate the curative effect of the BTXA@liposome nanoparticles on PSA. Through ECCA (échelle d'évaluation clinique des cicatrices d'acné) scoring and self-evaluation of patients, the resultant data indicated that compared to hyaluronic acid (HA) hydrogel treatment the BTXA@liposome/HA hydrogel treatment could better relieve PSA to some extent but didn't show significant advantage. Further work is needed to verify the feasibility and curative effect of this method in PSA treatment in the future.</p>","PeriodicalId":647,"journal":{"name":"Journal of Materials Science: Materials in Medicine","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286643/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Materials Science: Materials in Medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10856-024-06810-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

As an acne sequela, post-acne scarring (PSA) has huge negative impact on sufferers' quality of life because of aesthetical embarrassment. Transdermal delivery of botulinum toxin-A (BTXA) is a promising strategy for PAS treatment, but currently reported approaches are far from satisfactory. In this work, phosphatidylcholine/cholesterol (PC/Chol) nanoliposomes were utilized for encapsulation and transdermal delivery of BTXA. The composition, structure, morphology, size, size distribution, etc. of as-prepared BTXA@liposome nanoparticles were investigated in detail. Simulated transdermal delivery assay indicated that the diffusion depth of the BXTA@liposome nanoparticles was nearly 8 times that of pure BTXA and reached 380 μm. 12 facial PSA patients were recruited to evaluate the curative effect of the BTXA@liposome nanoparticles on PSA. Through ECCA (échelle d'évaluation clinique des cicatrices d'acné) scoring and self-evaluation of patients, the resultant data indicated that compared to hyaluronic acid (HA) hydrogel treatment the BTXA@liposome/HA hydrogel treatment could better relieve PSA to some extent but didn't show significant advantage. Further work is needed to verify the feasibility and curative effect of this method in PSA treatment in the future.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

通过磷脂酰胆碱/胆固醇纳米脂质体透皮输送肉毒杆菌毒素-A，用于治疗痤疮后瘢痕。

作为痤疮的后遗症，痤疮后瘢痕（PSA）会给患者带来美观上的尴尬，从而对其生活质量产生巨大的负面影响。透皮给药肉毒素-A（BTXA）是治疗痤疮后瘢痕的一种很有前景的方法，但目前报道的方法还远远不能令人满意。本研究利用磷脂酰胆碱/胆固醇（PC/Chol）纳米脂质体来封装和透皮给药 BTXA。详细研究了制备的 BTXA@脂质体纳米颗粒的组成、结构、形态、大小、粒度分布等。模拟透皮给药试验表明，BXTA@脂质体纳米颗粒的扩散深度是纯BTXA的近8倍，达到380 μm。为了评估 BTXA@脂质体纳米粒子对 PSA 的治疗效果，研究人员招募了 12 名面部 PSA 患者。通过ECCA（Echelle d'évaluation clinique des cicatrices d'acné）评分和患者自我评估，结果数据显示，与透明质酸（HA）水凝胶治疗相比，BTXA@脂质体/HA水凝胶治疗能在一定程度上更好地缓解PSA，但并没有显示出明显的优势。未来还需要进一步验证该方法在 PSA 治疗中的可行性和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Materials Science: Materials in Medicine 工程技术-材料科学：生物材料

CiteScore

8.00

自引率

0.00%

发文量

审稿时长

3.5 months

期刊介绍： The Journal of Materials Science: Materials in Medicine publishes refereed papers providing significant progress in the application of biomaterials and tissue engineering constructs as medical or dental implants, prostheses and devices. Coverage spans a wide range of topics from basic science to clinical applications, around the theme of materials in medicine and dentistry. The central element is the development of synthetic and natural materials used in orthopaedic, maxillofacial, cardiovascular, neurological, ophthalmic and dental applications. Special biomedical topics include biomaterial synthesis and characterisation, biocompatibility studies, nanomedicine, tissue engineering constructs and cell substrates, regenerative medicine, computer modelling and other advanced experimental methodologies.